| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,610,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.72 - $0.72 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Edesa Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases. Co.'s primary product candidates include: EB05, which is a monoclonal antibody therapy for the treatment for Acute Respiratory Distress Syndrome in COVID-19 patients; and EB01, which is a secretory phospholipase 2 (sPLA2) inhibitor for the topical treatment for chronic allergic contact dermatitis, a potentially debilitating condition and occupational illness. Co.'s EB02 drug candidate represents a potential extension of its sPLA2 anti-inflammatory technology. Co.'s product candidate EB06, is a monoclonal antibody candidate.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
5,000 |
5,000 |
5,000 |
31,000 |
| Total Buy Value |
$20,000 |
$20,000 |
$20,000 |
$61,378 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
1 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
297,474 |
| Total Sell Value |
$0 |
$0 |
$0 |
$787,716 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2020-03-29 |
4 |
B |
$5.23 |
$10,460 |
D/D |
2,000 |
547,312 |
0.01 |
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2020-03-17 |
4 |
B |
$1.83 |
$9,373 |
I/I |
5,000 |
2,121,024 |
0.01 |
- |
|
| Johnson Lorin K |
|
• • – |
2020-01-08 |
4/A |
A |
$4.11 |
$35,034 |
D/D |
8,524 |
8,524 |
|
- |
|
| Brooks Michael J |
President |
• • – |
2020-01-08 |
4/A |
A |
$4.11 |
$7,509 |
D/D |
1,827 |
1,827 |
|
- |
|
| Sistilli Carlo |
|
• • – |
2020-01-08 |
4/A |
A |
$4.11 |
$10,012 |
I/I |
2,436 |
2,436 |
|
- |
|
| Lumira Capital Investment Management Inc. |
|
• • • |
2020-01-08 |
4/A |
A |
$3.20 |
$450,000 |
I/I |
140,625 |
169,502 |
|
- |
|
| Pay Paul William |
|
• • – |
2020-01-08 |
4 |
A |
$4.11 |
$10,012 |
D/D |
2,436 |
2,436 |
|
- |
|
| Oakes Frank R. |
|
• • – |
2020-01-08 |
4 |
A |
$4.11 |
$5,006 |
I/I |
1,218 |
1,218 |
|
- |
|
| Pardeep Nijhawan Medicine Professional Corp |
Chief Executive Officer |
• • • |
2020-01-08 |
4 |
A |
$4.11 |
$38,038 |
I/I |
9,255 |
2,116,024 |
|
- |
|
| Niffenegger Kathi |
Chief Financial Officer |
• • – |
2020-01-08 |
4 |
A |
$4.11 |
$5,006 |
I/I |
1,218 |
1,218 |
|
- |
|
| Sistilli Carlo |
|
• • – |
2020-01-08 |
4 |
B |
$4.11 |
$10,012 |
I/I |
2,436 |
2,436 |
0.01 |
- |
|
| Johnson Lorin K |
|
• • – |
2020-01-08 |
4 |
B |
$4.11 |
$35,034 |
D/D |
8,524 |
8,524 |
0.01 |
- |
|
| Lumira Capital Investment Management Inc. |
|
• • • |
2020-01-08 |
4 |
B |
$3.20 |
$450,000 |
I/I |
140,625 |
169,502 |
0.01 |
- |
|
| Brooks Michael J |
President |
• • – |
2020-01-08 |
4 |
B |
$4.11 |
$7,509 |
D/D |
1,827 |
1,827 |
0.01 |
- |
|
| Oakes Frank R. |
|
• • – |
2019-09-11 |
4 |
S |
$5.72 |
$10,345 |
D/D |
(1,809) |
6,165 |
|
- |
|
| Macdonald Sean Arthur |
Director |
– • – |
2019-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
786 |
14,369 |
|
- |
|
| Lumira Capital Investment Management Inc. |
10% Owner |
– – • |
2019-07-26 |
4 |
A |
$0.00 |
$0 |
I/I |
101,606 |
157,599 |
|
- |
|
| Nijhawan Pardeep |
Chief Executive Officer |
• • • |
2019-07-26 |
4 |
A |
$0.00 |
$0 |
I/I |
130,933 |
224,094 |
|
- |
|
| Nijhawan Pardeep |
Chief Executive Officer |
• • • |
2019-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
30,183 |
537,312 |
|
- |
|
| Macdonald Sean Arthur |
Director |
– • – |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
13,583 |
13,583 |
|
- |
|
| Lumira Capital Investment Management Inc. |
10% Owner |
– – • |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
1,760,337 |
148,999 |
|
- |
|
| Nijhawan Pardeep |
Chief Executive Officer |
• • • |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
I/I |
2,199,930 |
211,506 |
|
- |
|
| Nijhawan Pardeep |
Chief Executive Officer |
• • • |
2019-06-07 |
4 |
A |
$0.00 |
$0 |
D/D |
507,129 |
507,129 |
|
- |
|
| Oakes Frank R. |
President & CEO |
• • – |
2019-03-06 |
4 |
AS |
$1.25 |
$5,000 |
D/D |
(4,000) |
47,924 |
|
- |
|
| Morse Daniel E. |
Former Director |
– – – |
2018-10-12 |
4 |
S |
$1.31 |
$9,260 |
D/D |
(7,047) |
20,741 |
|
- |
|
95 Records found
|
|
Page 3 of 4 |
|
|
